Article

Blended artificial tears may cause less blurring than high-viscosity agents

Fort Lauderdale, FL—A blended artificial tear product that combines high- and medium-viscosity sodium carboxymethylcellulose (CMC) causes less blurring compared with high-viscosity tears and might be more acceptable to patients, according to the results of a small clinical study.

Refresh Liquigel and Refresh Celluvisc tears (Allergan) caused a decrease in contrast sensitivity, but contrast sensitivity returned to baseline significantly faster with the Liquigel blended preparation, investigators reported at the Association for Research in Vision and Ophthalmology annual meeting.

"One of the main complaints people have about artificial tears is that when they put them in, there is blurring of vision," said James LaMotte, PhD, OD, a professor at the Southern California School of Optometry in Fullerton. "When you put in artificial tears and things are blurred for a couple of minutes, people don't like it. This product [Liquigel] reduces blurring but still maintains a more viscous tear that has a more soothing effect on the eye."

Temporal changes in tear film structure can distort the optical wavefront as artificial tears pass through the tear layer and can reduce contrast sensitivity. In theory, any substance applied to the tear that alters its structure could affect contrast sensitivity. Dr. LaMotte and colleagues examined how different formulations of CMC applied to the tear layer affect contrast sensitivity over time.

As a stimulus, the study participants viewed monocularly a stationary, vertically oriented sine wave grating (14 cyclesper degree). A temporal, two-alternative, forced-choice paradigm combined with a self-paced method of limits was employed to monitor threshold over time.

"Patients are presented with a sine wave grating and they blink, which triggers the device and displays the grating," said Dr. LaMotte. "There are two intervals, one with grating and one without, and the patient chooses between them. The program goes back and forth, so it will go above and below the threshold."

Monitoring contrast sensitivity

Following a baseline assessment, a drop of artificial tear was applied to the tear layer, and contrast sensitivity was monitored for 30 minutes, which allowed continual tracking of the threshold.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.